Refining Molecular Classification and Personalizing Therapy in Endometrial Cancer-Recording

Video Transcription

Video Summary

This session discusses advancements and practical implementation of molecular classification in uterine cancer management, highlighting its impact on treatment and prognosis. The session underscores the challenges of histotype and grade assignment disagreements among pathologists, which can significantly influence patient treatment. The Cancer Genome Atlas has helped develop molecular tools that classify endometrial cancers into four distinct prognostic groups, though initially complex, they are not practical for typical pathology labs. Subsequent surrogate tests using immunohistochemistry and sequencing have been developed, allowing for integration into clinical settings. The session further details the four molecular subgroups (pol-mutations, mismatch repair deficiency, P53 abnormal, and no specific molecular profile), their implications for treatment and prognosis, and the importance of early diagnosis and treatment decisions. It also touches on the practical application of these classifications in clinical practice and highlights the need for ongoing research and collaboration with pathologists.

Keywords

molecular classification

uterine cancer

prognostic groups

immunohistochemistry

clinical implementation